Key Takeaways:
Ipsen's Bylvay (odevixibat) failed to improve native liver survival in a Phase III trial for biliary atresia, a rare pediatric liver disease with no approved drug therapies, the company said Friday.
The BOLD trial enrolled 254 infants across 19 countries who had undergone Kasai hepatoportoenterostomy surgery within the first 90 days of life. Patients received either odevixibat at 120 micrograms per kilogram per day or a placebo for up to 104 weeks. The study did not meet its primary endpoint of improving native liver survival — defined as time from randomization to first liver transplant or death — versus placebo.
"The results reflect the significant challenge biliary atresia presents as a complex, rare pediatric cholestatic liver disease which has so far evaded all therapeutic attempts beyond surgery," Christelle Huguet, PhD, executive vice president and head of R&D at Ipsen, said.
Biliary atresia affects one in 5,000 to 20,000 newborns and is the leading cause of pediatric liver transplantation worldwide. The bile ducts inside or outside the liver become blocked or scarred, preventing bile from draining and causing progressive liver failure. While the Kasai procedure can restore bile flow, it does not cure the condition, and many patients still require a transplant.
Lead investigator Dr. Saul J. Karpen, a pediatric hepatologist at Virginia Commonwealth University, said the trial generated "the most comprehensive dataset ever assembled" in biliary atresia and that further analyses may reveal whether outcomes differ across patient subgroups.
Bylvay, a once-daily ileal bile acid transport inhibitor, is already approved in the U.S. and European Union for cholestatic pruritus in progressive familial intrahepatic cholestasis and Alagille syndrome. The failure limits near-term label expansion into biliary atresia, a market with no approved medical treatments.
Ipsen said it will conduct a comprehensive review of the full dataset before deciding whether to continue the open-label extension study, BOLD-EXT, which is evaluating longer-term safety and efficacy in patients who completed the BOLD trial.
The setback underscores the high-risk nature of rare disease drug development, where small patient populations and complex disease biology make late-stage success difficult. Ipsen's next catalyst will be any update on the BOLD-EXT extension study and potential subgroup analyses that could salvage a path forward for odevixibat in biliary atresia.
This article is for informational purposes only and does not constitute investment advice.
